About Us

  /  

Josh Murtie

VP Biology

Josh joins Cedilla from Servier Pharmaceuticals where he served as the head of cancer biology, in vivo pharmacology, and early stage program management.  Earlier in his career he held multiple roles during his 7 years at Agios Pharmaceuticals including head of in vivo pharmacology and head of cancer biology where he was responsible for strategic oversight of the company’s oncology portfolio from early target discovery to translational research.  Josh began his industry career with positions at NIBR and Sanofi.  He holds a Ph.D. in molecular and cell biology from the Uniformed Services University and completed his postdoctoral fellowship at Harvard Medical School.